HER2

(Lancet 2017;389: 2415)

HER2- targeted

• Trastuzumab (anti-HER2): 1st-line Rx combined w/ chemo
• Trastuzumab emtansine (mAb linked to chemo): ↓ risk of recurrence/death if residual disease post neoadj. Rx (NEJM 2019;380:617); preferred 2nd line Rx for met. disease
• Trastuzumab deruxtecan (mAb linked to chemo): emerging data as 2nd line Rx for met disease, ↓ risk disease progression vs. trastuzumab emtansine, ↑ lung toxicity (NEJM 2022;386:1143)
• Margetuximab (anti-HER2): combined w/ chemo preferred after 2+ lines of Rx (JAMA Oncol 2021;7:573)
• from Ado-trastuzumab emtansine